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We report the rescue results of intravitreal aﬂibercept in patients with treatment-resistant neovascular
age-related macular degeneration (AMD). We retrospectively analyzed eyes with neovascular AMD
resistant to posterior subtenon triamcinolone, intravitreal ranibizumab, and/or bevacizumab treatment
in a tertiary medical center in middle Taiwan between December 2013 and October 2014. We then
switched treatment to 2.0 mg aﬂibercept. The main outcome included changes in best-corrected visual
acuity and central foveal thickness measured by optical coherence tomography during monthly follow-
up. There were 204 patients with neovascular AMD, and the percentage of refractory cases was 1.96% (4
of 204 cases). Our study included ﬁve eyes of four patients that were resistant to multiple treatments and
subsequently switched to aﬂibercept. The mean age was 71.25 ± 11.09 years (range 57e83 years).
Treatments were on average 6.6 times previously. Upon switching to aﬂibercept treatment, the average
central foveal thickness on optical coherence tomography was 505.6 ± 270.86 mm (range 150e815 mm).
After aﬂibercept treatment, the average central foveal thickness was 192 ± 51.76 mm (range 149e274 mm).
All patients showed anatomic improvement, and 80% of the eyes (4 of 5 eyes) had improved best-
corrected visual acuity and 20% of the eyes (1 of 5 eyes) had stable visual acuity. Patients tolerated
the treatment well without serious adverse events. This short-term study showed that intravitreal
aﬂibercept was effective and safe in treatment-resistant neovascular AMD cases. However, analysis of
more cases and long-term follow-ups are mandatory.
Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Age-related macular degeneration (AMD) is the leading cause of
irreversible blindness in developed countries and accounts for 8.7%
of blindness worldwide. The age-speciﬁc prevalence of late AMD in
Asian populations is comparable with that reported in Caucasian
populations.1,2 Prominent advances in antiangiogenesis therapy
have revolutionized the management of neovascular AMD. The
current standard therapy includes posterior subtenononﬂicts of interest related to
ogy, China Medical University
n.
ciety of Taiwan. Published by Elsetriamcinolone and intravitreal administration of monoclonal
antibody-based therapies directed against vascular endothelial
growth factor (VEGF). The two most widely used drugs are rani-
bizumab (Lucentis; Genentech Inc., South San Francisco, CA, USA), a
recombinant VEGF-speciﬁc antibody fragment, and bevacizumab
(Avastin; Genentech Inc.), a monoclonal VEGF-speciﬁc antibody.
Several studies revealed that patients with AMD had favorable vi-
sual and anatomic responses to ranibizumab, bevacizumab, and/or
triamcinolone.1e14 However, there were still reports of patients
who had a good initial response to ranibizumab or bevacizumab,
but became resistant with decreased response over time to further
intravitreal injections. Although themechanism of this resistance is
not yet clear, tachyphylaxis may be the reason.3e6
Aﬂibercept (EYLEA; Regeneron Pharmaceuticals, Inc., Tarry-
town, New York, NY, USA, and Bayer Healthcare Pharmaceuticals,
Berlin, Germany), a recombinant fusion protein that binds tovier Taiwan LLC. All rights reserved.
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Food and Drug Administration for the treatment of exudative AMD
in November 2011 and by the Taiwan Food and Drug Administra-
tion in June 2013. The Vascular Endothelial Growth Factor Trap-
Eye: Investigation of Efﬁcacy and Safety in Wet Age-Related Mac-
ular Degeneration (VIEW) studies proved the safety and efﬁcacy of
the treatment.7 Aﬂibercept binds to all VEGF-A and VEGF-B iso-
forms, as well as to placenta growth factor, and has a greater
binding afﬁnity for VEGF molecules than for either ranibizumab or
bevacizumab.8,9 Cheng and Chan10 also reported a local case of
neovascular AMD, in which a rapid response to intravitreal aﬂi-
bercept was observed after development of tachyphylaxis to bev-
acizumab and/or ranibizumab. Therefore, we conducted this
retrospective study, and discovered favorable anatomic and func-
tional outcomes in patients with previously treatment-resistant
AMD in a tertiary medical center in central Taiwan.
2. Methods
We conducted a retrospective, noncomparative, consecutive,
interventional case series study. We retrospectively analyzed the
eyes of patients with neovascular AMD that were resistant to pos-
terior subtenon triamcinolone, intravitreal ranibizumab, or bev-
acizumab treatment, and then switched to aﬂibercept treatment
between December 2013 and October 2014. Informed oral and
written consents were obtained from all patients. The inclusion
criteria are as follows: (1) eyes with the diagnosis of neovascular
AMD [the presentation of drusen and choroidal neovascularization,
conﬁrmed by ﬂuorescein angiography and optical coherence to-
mography (OCT), and having passed the peer review of Taiwan
National Health Insurance for ranibizumab]; (2) having previously
been injected with posterior subtenon triamcinolone, intravitreal
bevacizumab, and/or ranibizumab, and followed by increasing or
persistent subretinal ﬂuid or retinal edema onOCT; and (3) the ﬂuid
having to be refractory to at least three monthly injections prior to
the ﬁrst aﬂibercept injection. The criteria for treatment with aﬂi-
bercept were the same as the retreatment criteria for bevacizumab
or ranibizumab regarding the presence of intraretinal or subretinal
ﬂuid. We recorded general data, including data on patient age, race,
sex, laterality, medical history, BCVA, intraocular pressure, and re-
sults of external ocular and slit-lamp examinations. Each patient
had a thorough bilateral fundus examination with indirect
ophthalmoscopy, fundus photographs, ﬂuorescein angiography,
and spectral-domain OCT (Cirrus HD-OCT; Carl Zeiss Meditec, Inc.,
Dublin, CA, USA) scans. All patients received at least one intravitreal
aﬂibercept injection (2.0 mg/0.05 mL) under topical anesthesia as
rescue treatment. Prior to the intravitreal injection, the pupils were
dilated with 1% tropicamide (Mydriacyl; Alcon Co., Belgium, USA),
and the topical antibiotic levoﬂoxacin (Cravit; Santen Pharmaceu-
tical Co., Osaka, Japan) was applied before the intravitreal in-
jections. Topical anesthesia with 0.5% proparacain hydrochloride
(Alcaine; Alcon Pharmaceuticals, Belgium) was given at 2-minute
intervals prior to the surgery. Each eye was prepared in a sterile
manner using 5% povidone/iodine. Aﬂibercept (2 mg/0.05 mL) was
injected intravitreally via the pars plana (3.5 mm away from the
limbus). Levoﬂoxacin eyedrops were given four times daily for 1
week. Information on the methods of initial management and
number of subsequent treatments was collected. The ﬁnal anatomic
outcome, ﬁnal BCVA, and complications were reviewed, and
changes in vision and retinal status were recorded. The main
outcome measures included changes in BCVA and central foveal
thickness (CFT), measured by spectral-domain OCT scan during
monthly follow-up. All cases were followed up for more than 2
months. We analyzed data including patient age, fundus ﬁndings
and follow-up period.3. Results
In our hospital, 204 patients with neovascular AMD were
treated between December 2013 and October 2014. Among them,
only ﬁve eyes of four cases were refractory to posterior subtenon
triamcinolone, intravitreal bevacizumab, and/or ranibizumab
treatment. The percentage of the refractory cases is 1.96%. Our
study analyzed a total of ﬁve eyes from four patients resistant to
multiple treatments with posterior subtenon triamcinolone,
intravitreal bevacizumab, and/or ranibizumab, who were subse-
quently switched to a minimum of one injection of aﬂibercept
(Table 1). The patients included ﬁve men and one woman. The
mean age was 71.25 ± 11.09 years (range 57e83 years). The per-
centage of our refractory AMD cases is 1.96% (4 of 204 cases). They
were all responsive to aﬂibercept for rescue therapy (100%). The
patients had received an average of 6.6 (range 3e10) previous
posterior subtenon triamcinolone, intravitreal ranibizumab, and/or
bevacizumab injections. Upon switching to aﬂibercept treatment,
the average CFT on OCT was 505.6 ± 270.86 mm (range
150e815 mm). After switching to aﬂibercept, the patients were
treated and followed up monthly. Each eye received an average of
3.8 aﬂibercept injections (range 1e7). We followed up with these
patients for 2e11 months. After intravitreal aﬂibercept treatment,
the average CFT measured by OCT was 192 ± 51.76 mm (range
149e274 mm). Compared with the visit before the ﬁrst injection of
aﬂibercept, there was a signiﬁcant average decrease (by 313.6 mm)
in CFT. All eyes showed anatomic improvement after switching to
aﬂibercept treatment. The baseline and changes in OCT scans for all
ﬁve eyes before and after intravitreal aﬂibercept treatment are
illustrated in Fig. 1. The results showed that 80% of the eyes (4 of 5
eyes) had improved BCVA, and 20% of the eyes (1 of 5 eyes) had
stabilization of visual acuity. Patients tolerated the treatment well
without serious adverse events, such as endophthalmitis, nonin-
fectious endophthalmitis, vitreous hemorrhage, retinal tear, retinal
detachment, or sustained elevations in pressure.
4. Discussion
This retrospective interventional case series in a tertiarymedical
center in central Taiwan studied the treatment response of eyes
with neovascular AMD that developed resistance to treatments
with posterior subtenon triamcinolone, intravitreal bevacizumab,
and/or ranibizumab, and were subsequently switched to a mini-
mum of one injection of aﬂibercept. We administered triamcino-
lone by posterior subtenon instead of intravitreal injection due to
the concerns of the complications of cataract and increased intra-
ocular pressure. In this study, the refractory cases were a minority.
Of a total of 204 cases, only four were refractory to posterior sub-
tenon triamcinolone, intravitreal bevacizumab, and/or ranibizu-
mab. The percentage of the refractory cases is 1.96%, and there were
no related studies that mentioned about this ratio.
As shown by several current reports,8e12 our study demon-
strated anatomic and visual improvement after switching to aﬂi-
bercept in cases with persistent macular edema despite prior anti-
VEGF treatments. The protocol of intravitreal aﬂibercept treatment
in the recent studies was mostly three monthly loading doses fol-
lowed by bimonthly injections. As our patients had to pay ~40,000
NT dollars for one aﬂibercept injection at that time, we treated the
four of ﬁve eyes with three monthly loading doses followed by prn
injections when recurrent macular edema occurred.
Our study revealed two main explanations for the improve-
ment: the pharmacodynamics of aﬂibercept and the possible
tachyphylaxis to prior treatment with ranibizumab or bev-
acizumab. First, aﬂibercept binds to all isoforms of VEGF-A, VEGF-B,
and PlGF, with a signiﬁcantly higher binding afﬁnity for VEGF than
Table 1
Summary of basic demographics, CFT, and best-corrected visual acuity of ﬁve eyes of four patients with rescue aﬂibercept treatment of neovascular age-related macular
degeneration.
Case Age/sex Eye Pre-Tx BCVA Pre-Tx CFT (mm) PSTK IVB IVR Pre-IVA BCVA Pre-IVA CFT (mm) Interval (mo)a IVA Final BCVA Final CFT (mm) Follow-up (mo)
1 69/F OD (1) 0.01 476 3 3 2 0.01 670 1 7 0.1 274 11
OS (2) 0.2 217 0 0 5 0.05 150 1 3 0.6 146 11
2 83/M OD (3) CF at 15 cm 664 1 0 6 CF at 10 cm 583 1 1 0.05 194 2
3 76/M OD (4) 0.2 710 0 4 6 0.1 815 13 3 0.2 149 6
4 57/M OS (5) 0.01 313 0 0 3 0.01 310 1 5 0.09 197 3
BCVA¼ best-corrected visual acuity; CF¼ counting ﬁngers; CFT¼ central foveal thickness; F¼ female; HM¼ handmovement; IVA¼ intravitreal aﬂibercept; IVB¼ intravitreal
bevacizumab; IVR ¼ intravitreal ranibizumab; M ¼ male; No. ¼ number; OD ¼ right eye; OS ¼ left eye; PSTK ¼ posterior subtenon kenacort; Tx ¼ treatment.
a Interval represents the time between the last treatment of PSTK, IVB, or IVR and before the IVA and follow up the time between the last IVA treatment and the ﬁnal
outpatient visit.
Fig. 1. OCT scans in ﬁve eyes: (A) baseline OCT scans; (B) OCT scans before intravitreal aﬂibercept treatment; and (C) OCT scans after intravitreal aﬂibercept treatment. OCT ¼ optical
coherence tomography.
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models predict that a single intravitreal injection of aﬂibercept
2.0 mg lasts between 48 days and 83 days (compared with 30 days
for ranibizumab). Aﬂibercept thus may neutralize VEGF more
effectively.8 Second, tachyphylaxis, an acute decrease in there-
sponse to a drug after its initial dose or a series of small doses
administered, might be another possible mechanism for the
observed effect after switching to aﬂibercept.3e6
In our study, all eyes showed anatomic improvement after
switching to aﬂibercept treatment. Compared with the visit before
the ﬁrst injection of aﬂibercept, there was a signiﬁcant averagedecrease in CFT by 313.6 mm. The study showed that 80% of eyes had
improved BCVA and 20% had stabilized visual acuity after switching
to aﬂibercept. The disproportion between anatomic improvement
and functional outcome could be attributed to chronic photore-
ceptor degeneration and loss of photoreceptors, which might have
limited the visual potential.9 During at least 2 months of treatment,
a generally favorable safety proﬁle was observed for intravitreal
aﬂibercept, and currently no eyes developed signiﬁcant ocular
safety events such as endophthalmitis, noninfectious endoph-
thalmitis, vitreous hemorrhage, retinal tear, retinal detachment, or
sustained elevations in intraocular pressure.
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trolled retrospective design of the study, the use of Snellen visual
acuity and nonstandard treatment protocols, and a lack of consis-
tent performance of ﬂuorescein and indocyanine angiography prior
to switching to aﬂibercept. Nevertheless, this short-term study in a
tertiary medical center in central Taiwan showed that intravitreal
aﬂibercept treatment was effective and safe in eyes of neovascular
AMD that were resistant to triamcinolone, ranibizumab, and/or
bevacizumab. Treatment with aﬂibercept can be considered an
alternative rescue treatment in eyes with neovascular AMD that do
not respond to other anti-VEGF treatments. Further follow-up is
required to determine the long-term efﬁcacy of aﬂibercept treat-
ment in these treatment-resistant neovascular lesions.Funding/support
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